Jason Hoitt - Dec 8, 2022 Form 4 Insider Report for Provention Bio, Inc. (PRVB)

Signature
/s/ Thierry Chauche, as attorney-in-fact
Stock symbol
PRVB
Transactions as of
Dec 8, 2022
Transactions value $
$0
Form type
4
Date filed
12/9/2022, 07:31 PM
Previous filing
Jan 20, 2022
Next filing
Jan 11, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRVB Stock Option (right to buy) Award $0 +120K +54.55% $0.00 340K Dec 8, 2022 Common Stock, par value $0.0001 120K $14.97 Direct F1, F2, F3
transaction PRVB Stock Option (right to buy) Award $0 +20.7K +37.5% $0.00 75.8K Dec 8, 2022 Common Stock, par value $0.0001 20.7K $12.62 Direct F2, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 As previously reported on a Form 4 filed on January 8, 2020, on January 7 2020, the Reporting Person was granted a stock option for 400,000 shares of Common Stock, 160,000 of which option shares vest in four equal annual installments commencing on January 7, 2021 and 240,000 of which option shares vest upon completion of certain performance milestones. This amount represents the vesting of 120,000 of the 240,000 performance option shares on December 8, 2022 upon the satisfaction of certain performance milestones. This Form 4 is being filed solely to report the vesting of such previously reported 120,000 option shares.
F2 The stock options were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan.
F3 Represents the 160,000 time-based option shares referred to in footnote (1) plus the 120,000 vested performance option shares referred to in footnote (1) plus 60,000 vested performance shares which vested on September 2, 2020.
F4 As previously reported on a Form 4 filed on July 16, 2020, on July 15, 2020 the Reporting Person was granted a stock option for 137,750 shares of Common Stock, 55,100 of which option shares vest in four equal annual installments commencing on July 15, 2021 and 82,650 of which option shares vest upon completion of certain performance milestones. This amount represents the vesting of 20,663 of the 82,650 performance option shares on December 8, 2022 upon the satisfaction of certain performance milestones. This Form 4 is being filed solely to report the vesting of such previously reported 20,663 option shares.
F5 Represents the 55,100 time-based option shares referred to in footnote (1) plus the 20,663 vested performance option shares referred to in footnote (4).